{"protocolSection": {"identificationModule": {"nctId": "NCT00545584", "orgStudyIdInfo": {"id": "0431-078"}, "secondaryIdInfos": [{"id": "2007_023"}], "organization": {"fullName": "Merck Sharp & Dohme LLC", "class": "INDUSTRY"}, "briefTitle": "Addition Of Januvia (Sitagliptin) Improves Glycemic Control In Patients Inadequately Controlled By Metformin (MK0431-078)", "officialTitle": "Multicenter, Open, Pragmatic, Randomized Trial Comparing the Efficacy of 3 Different Lifestyle Interventions After Addition of Sitagliptin to Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Therapy"}, "statusModule": {"statusVerifiedDate": "2017-04", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2007-04-01", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2009-11-19", "type": "ACTUAL"}, "completionDateStruct": {"date": "2009-11-19", "type": "ACTUAL"}, "studyFirstSubmitDate": "2007-10-16", "studyFirstSubmitQcDate": "2007-10-16", "studyFirstPostDateStruct": {"date": "2007-10-17", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2011-04-19", "resultsFirstSubmitQcDate": "2011-04-19", "resultsFirstPostDateStruct": {"date": "2011-05-11", "type": "ESTIMATED"}, "dispFirstSubmitDate": "2010-11-18", "dispFirstSubmitQcDate": "2011-02-17", "dispFirstPostDateStruct": {"date": "2011-03-08", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2017-04-07", "lastUpdatePostDateStruct": {"date": "2017-05-12", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Merck Sharp & Dohme LLC", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "To compare the efficacy of three strategies of lifestyle changes associated with Januvia (sitagliptin) 100 mg/day in patients with Type 2 Diabetes Mellitus (T2DM) inadequately controlled by metformin (hemoglobin A1c \\[HbA1c\\] 6.5-9%). A difference between the three strategies of lifestyle changes was expected."}, "conditionsModule": {"conditions": ["Diabetes Mellitus, Non-Insulin-Dependent"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 1512, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Sitagliptin with Standard of Care", "type": "EXPERIMENTAL", "description": "Subjects received sitagliptin 100 mg once daily for 26 Weeks, and: No specific intervention (standard recommendation) on physical exercise and diet.", "interventionNames": ["Drug: sitagliptin phosphate"]}, {"label": "Sitagliptin with Diet Advice", "type": "EXPERIMENTAL", "description": "Subjects received sitagliptin 100 mg once daily for 26 Weeks,\n\nand:\n\nIntervention on diet which includes advice on diet with a leaflet and a diary", "interventionNames": ["Drug: sitagliptin phosphate", "Behavioral: Comparator: Diet"]}, {"label": "Sitagliptin with Diet and Physical Activity Advice", "type": "EXPERIMENTAL", "description": "Subjects received sitagliptin 100 mg once daily for 26 Weeks,\n\nand:\n\nIntervention on diet + physical activity which includes advice on diet and physical activity with leaflets and diaries PLUS advice on physical activity with the utilization of a pedometer: subjects were asked to walk 10,000 steps per day 5 or more days per week.", "interventionNames": ["Drug: sitagliptin phosphate", "Behavioral: Comparator: Diet", "Behavioral: Comparator: Physical Activity"]}], "interventions": [{"type": "DRUG", "name": "sitagliptin phosphate", "description": "sitagliptin 100 mg once daily. Duration of treatment: 26 Weeks", "armGroupLabels": ["Sitagliptin with Diet Advice", "Sitagliptin with Diet and Physical Activity Advice", "Sitagliptin with Standard of Care"]}, {"type": "BEHAVIORAL", "name": "Comparator: Diet", "description": "Diet", "armGroupLabels": ["Sitagliptin with Diet Advice", "Sitagliptin with Diet and Physical Activity Advice"]}, {"type": "BEHAVIORAL", "name": "Comparator: Physical Activity", "description": "Physical Activity", "armGroupLabels": ["Sitagliptin with Diet and Physical Activity Advice"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Hemoglobin A1c Measurement", "description": "Hemoglobin A1c (HbA1c) is a measure of glycated hemoglobin in the blood. HbA1c greater than 6.5% was considered inadequately controlled.", "timeFrame": "Baseline and Week 24"}], "secondaryOutcomes": [{"measure": "Fasting Plasma Glucose (FPG) Measurement", "description": "Generally FPG values of \\~5.0-7.2 mmol/L would be considered goal (American Diabetes Association).", "timeFrame": "Baseline and Week 24"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Man or woman aged \\>/= 18 years,with T2DM and treated with the maximal tolerated dose of metformin, with documented or high likely inadequate control of diabetes (HbA1c 6.5-9%)\n\nExclusion Criteria:\n\n* Daily insulin treatment or one insulin dose or more within the last 8 weeks or expected insulin treatment within the next 3 months.\n* Hypoglycemia unawareness or recurrent major hypoglycemia or history of acidoketosis\n* Known hypersensitivity or contraindication to metformin", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Medical Monitor", "affiliation": "Merck Sharp & Dohme LLC", "role": "STUDY_DIRECTOR"}]}, "ipdSharingStatementModule": {"ipdSharing": "YES", "description": "http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf\n\nhttp://engagezone.msd.com/ds_documentation.php"}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "1512 subjects were selected/screened, 380 subjects failed screening, leaving 1132 subjects who were randomized.", "groups": [{"id": "FG000", "title": "Sitagliptin With Standard of Care", "description": "Subjects received sitagliptin 100 mg once daily for 26 Weeks,\n\nand:\n\nNo specific intervention (standard recommendation) on physical exercise and diet."}, {"id": "FG001", "title": "Sitagliptin With Diet Advice", "description": "Subjects received sitagliptin 100 mg once daily for 26 Weeks,\n\nand:\n\nIntervention on diet which includes advice on diet with a leaflet and a diary"}, {"id": "FG002", "title": "Sitagliptin With Diet and Physical Activity Advice", "description": "Subjects received sitagliptin 100 mg once daily for 26 Weeks,\n\nand:\n\nIntervention on diet + physical activity which includes advice on diet and physical activity with leaflets and diaries PLUS advice on physical activity with the utilization of a pedometer: subjects were asked to walk 10,000 steps per day 5 or more days per week."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "412"}, {"groupId": "FG001", "numSubjects": "414"}, {"groupId": "FG002", "comment": "306 subjects were randomized but only 305 were treated.", "numSubjects": "306"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "333"}, {"groupId": "FG001", "numSubjects": "334"}, {"groupId": "FG002", "numSubjects": "250"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "79"}, {"groupId": "FG001", "numSubjects": "80"}, {"groupId": "FG002", "numSubjects": "56"}]}], "dropWithdraws": [{"type": "Only one reason for discontinuation", "reasons": [{"groupId": "FG000", "numSubjects": "62"}, {"groupId": "FG001", "numSubjects": "61"}, {"groupId": "FG002", "numSubjects": "48"}]}, {"type": "Two or more reasons for discontinuation", "reasons": [{"groupId": "FG000", "numSubjects": "17"}, {"groupId": "FG001", "numSubjects": "19"}, {"groupId": "FG002", "numSubjects": "8"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Sitagliptin With Standard of Care", "description": "Subjects received sitagliptin 100 mg once daily for 26 Weeks,\n\nand:\n\nNo specific intervention (standard recommendation) on physical exercise and diet."}, {"id": "BG001", "title": "Sitagliptin With Diet Advice", "description": "Subjects received sitagliptin 100 mg once daily for 26 Weeks,\n\nand:\n\nIntervention on diet which includes advice on diet with a leaflet and a diary"}, {"id": "BG002", "title": "Sitagliptin With Diet and Physical Activity Advice", "description": "Subjects received sitagliptin 100 mg once daily for 26 Weeks,\n\nand:\n\nIntervention on diet + physical activity which includes advice on diet and physical activity with leaflets and diaries PLUS advice on physical activity with the utilization of a pedometer: subjects were asked to walk 10,000 steps per day 5 or more days per week."}, {"id": "BG003", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "362"}, {"groupId": "BG001", "value": "358"}, {"groupId": "BG002", "value": "265"}, {"groupId": "BG003", "value": "985"}]}], "measures": [{"title": "Age, Continuous", "description": "The Full Analysis Set (FAS) population included all selected patients with at least one measured HbA1c value after Visit 2 and having received at least one dose of sitagliptin.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "58.26", "spread": "10.04"}, {"groupId": "BG001", "value": "57.47", "spread": "9.12"}, {"groupId": "BG002", "value": "57.30", "spread": "9.90"}, {"groupId": "BG003", "value": "57.71", "spread": "9.68"}]}]}]}, {"title": "Sex: Female, Male", "description": "The Full Analysis Set (FAS) population included all selected patients with at least one measured HbA1c value after Visit 2 and having received at least one dose of sitagliptin.", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "181"}, {"groupId": "BG001", "value": "175"}, {"groupId": "BG002", "value": "126"}, {"groupId": "BG003", "value": "482"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "181"}, {"groupId": "BG001", "value": "183"}, {"groupId": "BG002", "value": "139"}, {"groupId": "BG003", "value": "503"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Hemoglobin A1c Measurement", "description": "Hemoglobin A1c (HbA1c) is a measure of glycated hemoglobin in the blood. HbA1c greater than 6.5% was considered inadequately controlled.", "populationDescription": "The Full Analysis Set (FAS) population included all selected patients with at least one measured HbA1c value after Visit 2 and having received at least one dose of sitagliptin. In the Standard of Care group, only 360 subjects had HbA1c Baseline evaluations.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percent HbA1c", "timeFrame": "Baseline and Week 24", "groups": [{"id": "OG000", "title": "Sitagliptin With Standard of Care", "description": "Subjects received sitagliptin 100 mg once daily for 26 Weeks,\n\nand:\n\nNo specific intervention (standard recommendation) on physical exercise and diet."}, {"id": "OG001", "title": "Sitagliptin With Diet Advice", "description": "Subjects received sitagliptin 100 mg once daily for 26 Weeks,\n\nand:\n\nIntervention on diet which includes advice on diet with a leaflet and a diary"}, {"id": "OG002", "title": "Sitagliptin With Diet and Physical Activity Advice", "description": "Subjects received sitagliptin 100 mg once daily for 26 Weeks,\n\nand:\n\nIntervention on diet + physical activity which includes advice on diet and physical activity with leaflets and diaries PLUS advice on physical activity with the utilization of a pedometer: subjects were asked to walk 10,000 steps per day 5 or more days per week."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "362"}, {"groupId": "OG001", "value": "358"}, {"groupId": "OG002", "value": "265"}]}], "classes": [{"title": "Baseline (n=360, 358, and 265, respectively)", "categories": [{"measurements": [{"groupId": "OG000", "value": "7.37", "spread": "0.61"}, {"groupId": "OG001", "value": "7.50", "spread": "0.66"}, {"groupId": "OG002", "value": "7.49", "spread": "0.60"}]}]}, {"title": "Week 24 (n=362, 358, and 265, respectively)", "categories": [{"measurements": [{"groupId": "OG000", "value": "7.33", "spread": "1.09"}, {"groupId": "OG001", "value": "7.42", "spread": "1.15"}, {"groupId": "OG002", "value": "7.40", "spread": "1.07"}]}]}]}, {"type": "SECONDARY", "title": "Fasting Plasma Glucose (FPG) Measurement", "description": "Generally FPG values of \\~5.0-7.2 mmol/L would be considered goal (American Diabetes Association).", "populationDescription": "FAS population. Furthermore, only 350, 252, and 350 subjects had FPG evaluations in the Diet advice, Diet \\& physical activity advice, and Standard groups, respectively, at Baseline; and 303, 224, and 310 subjects had FPG evaluations in the Diet advice, Diet \\& physical activity advice, and Standard groups, respectively, at Week 24.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmol/L glucose", "timeFrame": "Baseline and Week 24", "groups": [{"id": "OG000", "title": "Sitagliptin With Standard of Care", "description": "Subjects received sitagliptin 100 mg once daily for 26 Weeks,\n\nand:\n\nNo specific intervention (standard recommendation) on physical exercise and diet."}, {"id": "OG001", "title": "Sitagliptin With Diet Advice", "description": "Subjects received sitagliptin 100 mg once daily for 26 Weeks,\n\nand:\n\nIntervention on diet which includes advice on diet with a leaflet and a diary"}, {"id": "OG002", "title": "Sitagliptin With Diet and Physical Activity Advice", "description": "Subjects received sitagliptin 100 mg once daily for 26 Weeks,\n\nand:\n\nIntervention on diet + physical activity which includes advice on diet and physical activity with leaflets and diaries PLUS advice on physical activity with the utilization of a pedometer: subjects were asked to walk 10,000 steps per day 5 or more days per week."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "310"}, {"groupId": "OG001", "value": "303"}, {"groupId": "OG002", "value": "224"}]}], "classes": [{"title": "Baseline (n=350, 350, 252, respectively)", "categories": [{"measurements": [{"groupId": "OG000", "value": "8.87", "spread": "1.98"}, {"groupId": "OG001", "value": "9.00", "spread": "2.03"}, {"groupId": "OG002", "value": "8.91", "spread": "1.87"}]}]}, {"title": "Week 24 (n=310, 303, and 224, respectively)", "categories": [{"measurements": [{"groupId": "OG000", "value": "8.21", "spread": "2.07"}, {"groupId": "OG001", "value": "8.32", "spread": "2.08"}, {"groupId": "OG002", "value": "8.47", "spread": "2.17"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "This safety data includes AEs and SAEs that occurred during treatment (Visit 2 to Visit 4).", "eventGroups": [{"id": "EG000", "title": "Sitagliptin With Standard of Care", "description": "Subjects received sitagliptin 100 mg once daily for 26 Weeks,\n\nand:\n\nNo specific intervention (standard recommendation) on physical exercise and diet.", "seriousNumAffected": 8, "seriousNumAtRisk": 412, "otherNumAffected": 0, "otherNumAtRisk": 412}, {"id": "EG001", "title": "Sitagliptin With Diet Advice", "description": "Subjects received sitagliptin 100 mg once daily for 26 Weeks,\n\nand:\n\nIntervention on diet which includes advice on diet with a leaflet and a diary", "seriousNumAffected": 18, "seriousNumAtRisk": 414, "otherNumAffected": 0, "otherNumAtRisk": 414}, {"id": "EG002", "title": "Sitagliptin With Diet and Physical Activity Advice", "description": "Subjects received sitagliptin 100 mg once daily for 26 Weeks,\n\nand:\n\nIntervention on diet + physical activity which includes advice on diet and physical activity with leaflets and diaries PLUS advice on physical activity with the utilization of a pedometer: subjects were asked to walk 10,000 steps per day 5 or more days per week.", "seriousNumAffected": 7, "seriousNumAtRisk": 305, "otherNumAffected": 0, "otherNumAtRisk": 305}], "seriousEvents": [{"term": "IDIOPATHIC THROMBOCYTOPENIC PURPURA", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 412}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 414}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 305}]}, {"term": "ACUTE CORONARY SYNDROME", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 412}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 414}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 305}]}, {"term": "ADAMS-STOKES SYNDROME", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 412}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 414}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 305}]}, {"term": "ANGINA UNSTABLE", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 412}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 414}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 305}]}, {"term": "MYOCARDIAL INFARCTION", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 412}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 414}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 305}]}, {"term": "MACULAR OPACITY", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 412}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 414}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 305}]}, {"term": "INGUINAL HERNIA", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 412}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 414}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 305}]}, {"term": "CARDIAC DEATH", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 412}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 414}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 305}]}, {"term": "SUDDEN DEATH", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 412}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 414}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 305}]}, {"term": "CHOLECYSTITIS", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 412}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 414}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 305}]}, {"term": "ABDOMINAL WALL ABSCESS", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 412}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 414}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 305}]}, {"term": "EAR INFECTION", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 412}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 414}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 305}]}, {"term": "LARYNGITIS", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 412}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 414}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 305}]}, {"term": "PNEUMONIA", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 412}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 414}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 305}]}, {"term": "DRUG EXPOSURE DURING PREGNANCY", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 412}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 414}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 305}]}, {"term": "FRACTURE", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 412}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 414}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 305}]}, {"term": "LIMB TRAUMATIC AMPUTATION", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 412}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 414}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 305}]}, {"term": "LUMBAR VERTEBRAL FRACTURE", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 412}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 414}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 305}]}, {"term": "TENDON RUPTURE", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 412}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 414}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 305}]}, {"term": "DIABETES MELLITUS", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 412}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 414}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 305}]}, {"term": "OSTEOARTHRITIS", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 412}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 414}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 305}]}, {"term": "BREAST CANCER", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 412}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 414}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 305}]}, {"term": "FIBROMA", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 412}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 414}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 305}]}, {"term": "LUNG NEOPLASM MALIGNANT", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 412}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 414}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 305}]}, {"term": "PROSTATE CANCER", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 412}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 414}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 305}]}, {"term": "CERVICAL ROOT PAIN", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 412}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 414}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 305}]}, {"term": "ENCEPHALITIS", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 412}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 414}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 305}]}, {"term": "SCIATICA", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 412}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 414}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 305}]}, {"term": "SYNCOPE", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 412}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 414}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 305}]}, {"term": "DEPRESSION", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 412}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 414}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 305}]}, {"term": "SUICIDE ATTEMPT", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 412}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 414}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 305}]}, {"term": "RENAL NECROSIS", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 412}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 414}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 305}]}, {"term": "GENITAL PROLAPSE", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 412}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 414}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 305}]}, {"term": "PULMONARY EMBOLISM", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 412}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 414}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 305}]}, {"term": "RASH", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 412}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 414}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 305}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial."}, "pointOfContact": {"title": "Senior Vice President, Global Clinical Development", "organization": "Merck Sharp & Dohme Corp", "email": "ClinicalTrialsDisclosure@merck.com", "phone": "1-800-672-6372"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "removedCountries": ["France"]}, "conditionBrowseModule": {"meshes": [{"id": "D000003920", "term": "Diabetes Mellitus"}, {"id": "D000003924", "term": "Diabetes Mellitus, Type 2"}], "ancestors": [{"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "asFound": "Diabetes Mellitus", "relevance": "HIGH"}, {"id": "M7119", "name": "Diabetes Mellitus, Type 2", "asFound": "Diabetes Mellitus, Non-Insulin-Dependent", "relevance": "HIGH"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000068900", "term": "Sitagliptin Phosphate"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000054795", "term": "Incretins"}, {"id": "D000006728", "term": "Hormones"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D000054873", "term": "Dipeptidyl-Peptidase IV Inhibitors"}, {"id": "D000011480", "term": "Protease Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M11667", "name": "Metformin", "relevance": "LOW"}, {"id": "M335", "name": "Sitagliptin Phosphate", "asFound": "Dextromethorphan", "relevance": "HIGH"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}, {"id": "M27905", "name": "Incretins", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}, {"id": "M27957", "name": "Dipeptidyl-Peptidase IV Inhibitors", "relevance": "LOW"}, {"id": "M19609", "name": "HIV Protease Inhibitors", "relevance": "LOW"}, {"id": "M14343", "name": "Protease Inhibitors", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "Infe", "name": "Anti-Infective Agents"}]}}, "hasResults": true}